Lyell Immunopharma's 15min Chart Triggers MACD Death Cross, KDJ Death Cross, Bearish Marubozu

Lyell Immunopharma's 15-minute chart exhibited a MACD Death Cross, KDJ Death Cross, and a Bearish Marubozu at 08/18/2025 12:15. This suggests that the stock price has the potential to continue trending downward, with a shift in momentum toward the downside. Sellers are likely to dominate the market, and the bearish momentum is expected to persist.

Lyell Immunopharma's (LYEL) 15-minute chart exhibited significant bearish signals on August 18, 2025, at 12:15. The chart indicated a MACD Death Cross, KDJ Death Cross, and a Bearish Marubozu pattern. These technical indicators suggest a potential downward trend in the stock price, with sellers likely to dominate the market and bearish momentum expected to persist.

The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a change in momentum from bullish to bearish. The KDJ Death Cross, where the KDJ line crosses below the signal line, also signals a shift in momentum towards the downside. The Bearish Marubozu candlestick pattern, characterized by a long body without any upper or lower wicks, further supports this bearish sentiment by suggesting strong selling pressure with no reversal.

Analysts have provided a mixed outlook for Lyell Immunopharma. According to the latest data, out of three analysts, the mean earnings estimate fell by about 3.4% in the last three months, with one analyst negatively revising an earnings estimate. The current average analyst rating on the shares is "hold," with no "strong buy" or "buy" recommendations, one "hold," and one "sell" or "strong sell" recommendation [2].

Lyell Immunopharma reported a quarterly adjusted loss of $2.89 per share for the quarter ended June 30, 2025, which was higher than the same quarter last year. Revenue fell 38.5% to $8.00 thousand from a year ago, missing analysts' expectations of zero. The company's shares have risen by 19.7% this quarter but lost 17.3% so far this year [2].

Investors should be cautious, given the bearish technical signals and the mixed analyst outlook. Despite the company's focus on developing cell-based immunotherapies for human diseases, the recent quarterly results and technical indicators suggest a challenging period ahead.

References:
[1] https://www.cnn.com/markets/stocks/LYEL
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U41V7:0-lyell-immunopharma-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[3] https://www.ainvest.com/news/gravity-15min-chart-sees-macd-death-cross-kdj-death-cross-bearish-marubozu-2508/
[4] https://www.ainvest.com/news/mercadolibre-15min-chart-shows-kdj-death-cross-bearish-marubozu-2508/
[5] https://seekingalpha.com/news/4484262-lyell-immunopharma-files-to-sell-375m-shares-of-common-stock-for-holders